Overview

Study in Pediatric Subjects With Epilepsy

Status:
Terminated

Trial end date:
2013-04-29

Target enrollment:

Participant gender:

Summary

This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Collaborators:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Treatments:

Ezogabine